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Abstract
Despite increased availability of online promotional tools for prescription drug marketers, evidence on online 
prescription drug promotion is far from settled or conclusive. We highlight ways in which online prescription drug 
promotion is similar to conventional broadcast and print advertising and ways in which it differs. We also highlight 
five key areas for future research: branded drug website influence on consumer knowledge and behavior, interactive 
features on branded drug websites, mobile viewing of branded websites and mobile advertisements, online promotion 
and non-US audiences, and social media and medication decisions.
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As Kim1 notes, the emergence of online prescription drug promotion warrants research, both to inform regulation in countries that allow direct-to-consumer 
(DTC) promotion and to understand consumer behavior 
around the world. Although healthcare providers continue to 
be highly trusted sources of health information, consumers 
often first consult Internet-based sources to answer questions 
about health conditions or medications.2,3 At the same time, 
pharmaceutical companies are increasingly using online 
promotional tools, such as branded drug websites, online 
videos (eg, YouTube), and social media (eg, Facebook, Twitter, 
online forums, and chat rooms), to provide information about 
prescription drugs.4-8 Yet these online tools—as demonstrated 
by Kim and others9-11—often fail to present balanced 
information about prescription drug benefits and risks.
Despite the availability of online promotional tools, however, 
the evidence on online prescription drug promotion is far 
from conclusive. Kim’s study helps to address the need for 
new research; her overview of a decade of warning letters 
issued by the U.S. Food and Drug Administration (FDA) 
highlights some important observations. She notes that online 
promotion, like conventional broadcast and print advertising, 
harbors numerous instances of inaccurate description of drug 
benefits and risks. Unlike conventional broadcast advertising, 
however, online promotion can pose unique space constraints 
(such as character and space limits in Internet search engine 
results) that can make benefit and risk description challenging. 
Moreover, social media applications beg new questions about 
the influence of interpersonal communication online. 
From a regulatory perspective, we should examine additional 
dimensions in FDA warnings beyond Kim’s current analysis. 
Specifically, future research should compare online DTC 
warnings against conventional broadcast and print ad 
warnings, should distinguish between notices of violation and 
more serious warning letters, and should compare the volume 
of FDA warnings against the prevalence of each DTC activity. 
These assessments would help to identify how online DTC 
violations compare to traditional DTC violations and whether 
the high volume of warnings for branded drug websites is 
because such sites are more prevalent than other online DTC 
activities.
From a decision science perspective, we need to expand 
online DTC research beyond FDA warning letters to examine 
how online promotion influences consumer knowledge, 
perceptions, and decision-making. Although it is important 
to ensure that online DTC content is fair and balanced, we 
also need to understand what role this content—balanced 
or not—plays in consumer health and medication choices. 
As researchers look ahead to new investigations of online 
prescription drug promotion, we recommend five key areas 
for consideration.
Branded Drug Website Influence on Consumer Knowledge 
and Behavior
Relatively little research has examined how consumers 
navigate and use branded drug websites, how sites affect 
consumer knowledge of drug benefits and risks, or how 
consumer reactions to DTC websites differ from reactions 
to traditional DTC ads.8,12 Moreover, older age, lower health 
literacy, and use of multiple medications can interfere with 
comprehension of drug labels and risk information, and we 
need to understand whether these audiences also struggle 
to process or retain important information from drug 
websites.13-18
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Interactive Features on Branded Drug Websites
Branded websites can (and sometimes do) incorporate 
interactive features that cannot be included in traditional 
print and broadcast ads, such as video testimonials, symptom 
checklists, printable coupons, and hyperlinks to disease 
information or medical resources.10,19,20 However, research 
has not yet explored how interactive features influence 
consumer knowledge, perceptions, and behavior in this arena 
and whether their presence interferes with the fair balance of 
benefit and risk information mandated by FDA. 
Mobile Viewing of Branded Websites and Mobile 
Advertisements
Consumers increasingly access the Internet on mobile 
devices—such as smartphones and tablets—to seek health 
information online.21 However, many websites are still not 
optimized for mobile viewing, which can make it difficult for 
consumers to navigate sites.22 We have a limited understanding 
of whether consumers who visit non-optimized sites on mobile 
devices are able to find desired information, understand the 
benefits and risks of advertised drugs, and make appropriate 
decisions about the medications.
Along with the rise in mobile device use, marketers also are 
increasingly using mobile and targeted advertising to reach 
consumers.23-25 Consequently, we need to examine how 
often pharmaceutical companies employ mobile advertising, 
whether such advertising meets FDA’s requirements for fair 
balance, and how consumers react to these ads.
Online Promotion and Non-US Audiences
The United States and New Zealand are the only countries 
that permit DTC prescription drug advertising. However, 
unlike traditional print and broadcast ads, online DTC 
activities have the ability to cross international borders and be 
accessed by consumers in countries where DTC advertising 
is not legal.4 In fact, adults in Europe and Asia frequently 
seek medication information online, often accessing branded 
drug sites.26-28 This raises questions not only about the ability 
of FDA, the European Medicines Agency (EMA), and other 
agencies to regulate drug promotion online, but also about 
how adults around the world react to these activities.
Social Media, Drug Promotion, and Medication Decisions
The promotion of prescription drugs via social media is still 
a new phenomenon, and FDA’s guidance on social media 
promotion largely reiterates the general requirement for 
fair balance of benefit and risk information.4,29-30 However, 
consumer use of social media for health information has grown 
rapidly, and even though few pharmaceutical companies 
use social media to make drug product claims, consumers 
frequently discuss their own personal drug experiences—
including effectiveness and side effects—on social media.5,31-33 
Thus, we need to understand how pharmaceutical companies 
use social media, how consumers react to direct promotion 
(eg, product-specific Twitter feed) vs. subtle promotion (eg, 
online illness forum hosted by drug manufacturer), and how 
consumers use information gleaned from social media in 
their decisions.
Although relatively few of the warning letters in Kim’s1 sample 
directly involved social media, concerns over social media 
activities by prescription drug marketers are likely to increase 
in the future. Social media applications raise important 
challenges for researchers relative to conventional broadcast 
advertising. Consider, for example, the range of ways in which 
people—either affiliated or unaffiliated with pharmaceutical 
companies—can encounter and propagate content online.34 
People can discuss prescription drugs in online forums, 
forward medication information to others, and share offers or 
incentives for drug samples with others. Consumers also can 
explicitly endorse advertisements or messages (eg, “liking” a 
Facebook post). Although FDA has provided some guidance 
on how pharmaceutical companies should respond to such 
third-party endorsements,30 future research should investigate 
how consumers react to such endorsements and provide more 
concrete evidence to inform marketing guidelines.
With these ideas in mind, we face a robust research agenda 
for online prescription drug promotion. Building on Kim’s 
work, future contributors to this journal and the literature can 
improve our understanding of how consumers encounter and 
process prescription drug promotion online and, ultimately, 
how online promotion influences consumer behavior.
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